Jean-Francois Pariseau

Co-Founder and Partner

2018 - Current

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices.

Member Board Of Directors

2022

Board Member

2021

LQT Therapeutics, Inc. is pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias based on research from Beth Israel Deacons Medical Center, Massachusetts General Hospital, and Sanofi, S.A. By combining leading-edge cardiovascular genetics and diagnostics with recent advances in the understanding of the role of SGK1, LQT Therapeutics seeks to make a meaningful difference in the lives of people suffering from Long QT Syndrome and resistant cancers. LQT Therapeutics was founded by world-class experts in cardiovascular disease, cardiac muscle biology and drug development.

Board Member

2021

Réseau Capital, the Québec Venture Capital and Private Equity Association, is the only private equity association that brings together all stakeholders involved in the Quebec investment chain. The mission of Réseau Capital is to contribute to the development and efficient operation of the private equity industry, which plays a major role in the development and financing of businesses in Québec.

Associate

2019

Advisor

2013

Hacking Health is designed to improve healthcare by inviting technology creators and healthcare professionals to collaborate on realistic, human-centric solutions to front-line problems. Our hackathons and workshops are fun, intense, hands-on events where small teams tackle tough problems in a supportive community of peers and mentors.

Board Member

2015 - 2023

Imagia believes that the technology of deep learning is a key to the future of medical image processing, with its ability to merge large and diverse data sources to make more accurate predictions. Deep learning is working today, and is more capable to assist physicians than ever, improving early cancer diagnosis. Imagia bridges the gap between academic research and clinical practice, making this world-changing technology accessible to improve patient care.

Board Member

2011 - 2022

Profound Medical is a Canadian medical device company that has developed a unique, minimally invasive treatment to ablate the prostate gland. Profound's novel technology combines Magnetic Resonance Imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. Delivered via a trans-urethral approach, this method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. The potential of this technology is currently being demonstrated in Phase I clinical trials.

Board Member

2021 - 2022

Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

Board Member

2012 - 2018

Clementia is a privately-held, clinical stage biotechnology company dedicated to the development and commercialization of treatments for people living with rare diseases by exploiting the use of novel Retinoic acid receptor gamma agonists (RARγ) to address diseases of heterotopic ossification, including Fibrodysplasia Ossificans Progressiva.